Tailwinds' Take: with recent approvals from Kite and Novartis, along with 20 Phase III drug partnerships, Cryoport is poised to have explosive revenue growth over the next few years. As they say, "Tip of the iceberg." IRVINE, Calif., Nov. 2, 2017 /PRNewswire/...
IRVINE, Calif., Oct. 26, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company"), the world's leading cold chain logistics company serving the life sciences industry, today announced the launch of a new website supporting its CryoStork(SM) cryogenic logistics solutions...
Tailwinds' Take: CYRX holds a commanding position in the delivery of regenerative therapeutics. KITE's drug will be the second approved in this space. Expect more approvals and more Cryoport engagements going forward.  IRVINE, Calif., Sept. 5, 2017 /PRNewswire/ -- Cryoport (NASDAQ: CYRX, CYRXW)...
Tailwinds' Take: CYRX is in a sweet spot and will be for at least the next couple of years as they will continue to gain market share and revenue growth is set to go hyperbolic. The stock will likely...
Tailwinds' Take: This announcement was well anticipated, but great news nonetheless. Revenue guidance of $8-10M per annum from this contract is double trailing 12 month revenues, so the upside is huge. Expect to see Kite contract announced in not...
IRVINE, Calif., June 19, 2017 /PRNewswire/ -- The Cryoport Biotech Activity Index (the "CoBRA IndexSM") quantifies the activity in the development and clinical trials of regenerative therapies in the United States, and acts as a means by which investors, the media...
Tailwinds' Take: CYRX's competitive strength will result in a number of partner relationships going forward as more trials move towards Phase III and commercialization.  IRVINE, Calif., June 7, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW), the world's leading cryogenic logistics...
This video details the competitive strength and upcoming catalysts for CYRX.
I often refer to Silicon Valley as having a printing press for making money. It literally seems to grow on trees not only down in the valley, but in the whole Bay Area. However, despite the conception of every...
Tailwinds' Take: 27 new clients and 14 new trials demonstrates the strength of their competitive positioning in the growing biopharma space. The company is on the verge of a hockey stick inflection as more trials proceed through phases 1,...